Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$19.0M
Filings
185
Firms Hired
7
Active Period
2013–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
New Era of Preventing End-Stage Kidney Disease Act
2026 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Client expense: $310,000 · Firm income: —
Matched citations: H.R. 1518
Safe Step Act
2026 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Client expense: $310,000 · Firm income: —
Matched citations: HR 5509
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Client expense: $310,000 · Firm income: —
Matched citations: S. 2903
New Era of Preventing End-Stage Kidney Disease Act
2026 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Client expense: $1,240,000 · Firm income: —
Matched citations: H.R. 1518
Safe Step Act
2026 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Client expense: $1,240,000 · Firm income: —
Matched citations: HR 5509
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Client expense: $1,240,000 · Firm income: —
Matched citations: S. 2903
New Era of Preventing End-Stage Kidney Disease Act
2026 · first_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 1518
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2025 · fourth_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act, concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 1
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · fourth_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
Client expense: $1,030,000 · Firm income: —
Matched citations: HR 1492
EPIC Act of 2025
2025 · fourth_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
Client expense: $1,030,000 · Firm income: —
Matched citations: S.832
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2025 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.
Client expense: $340,000 · Firm income: —
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.
Client expense: $340,000 · Firm income: —
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Client expense: $340,000 · Firm income: —
Matched citations: H.R. 1
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Client expense: $340,000 · Firm income: —
Matched citations: HR 1492
EPIC Act of 2025
2025 · third_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Client expense: $340,000 · Firm income: —
Matched citations: S.832
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. Education about innovative therapies treating Alzheimer's dementia and access to innovative therapies in Medicare.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2025 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.
Client expense: $1,160,000 · Firm income: —
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Client expense: $1,160,000 · Firm income: —
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.
Client expense: $1,160,000 · Firm income: —
Matched citations: H.R. 1
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Client expense: $1,160,000 · Firm income: —
Matched citations: HR 1492
EPIC Act of 2025
2025 · second_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Client expense: $1,160,000 · Firm income: —
Matched citations: S.832
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · first_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).
Client expense: $1,180,000 · Firm income: —
Matched citations: HR 1492
EPIC Act of 2025
2025 · first_quarter · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).
Client expense: $1,180,000 · Firm income: —
Matched citations: S.832
Source: Senate LDA